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Copper relay path through the N-terminus of
Wilson disease protein, ATP7B†
Kumaravel Ponnandai Shanmugavel and Pernilla Wittung-Stafshede *
In human cells, copper (Cu) ions are transported by the cytoplasmic Cu chaperone Atox1 to the Wilson
disease protein (ATP7B) in the Golgi for loading of Cu-dependent enzymes. ATP7B is a membrane-
spanning protein which, in contrast to non-mammalian homologs, has six cytoplasmic metal-binding
domains (MBDs). To address the reason for multiple MBDs, we introduced strategic mutations in which
one, two or three MBDs had been blocked for Cu binding via cysteine-to-serine mutations (but all six
MBDs are present in all) in a yeast system that probes Cu flow through Atox1 and ATP7B. The results,
combined with earlier work, support a mechanistic model in which MBD1-3 forms a regulatory unit of
ATP7B Cu transport. Cu delivery via Atox1 to this unit, followed by loading of Cu in MBD3, promotes
release of inhibitory interactions. Whereas the Cu site in MBD4 can be mutated without a large effect, an
intact Cu site in either MBD5 or MBD6 is required for Cu transport. All MBDs, expressed as single-domain
proteins, can replace Atox1 and deliver Cu to full-length ATP7B. However, only MBD6 can deliver Cu to
truncated ATP7B where all six MBDs are removed, suggesting a docking role for this structural unit.
Significance to metallomics
Copper is an essential metal ion facilitating biological function but can also promote human disease. To avoid toxicity of free copper ions, there are protein-
based transport systems that deliver the metal to target proteins. Many questions around human copper transport proteins remain unanswered. We here used a
yeast system that probes copper flow through the human copper transport proteins Atox1 and ATP7B to investigate how Cu is shuttled among ATP7B’s unique
set of six metal-binding domains. The yeast assay can be expanded to probe many mechanistic questions around copper transport and for investigations of
human diseases involving Cu misbalance.
Introduction
Copper (Cu) ions in oxidized and reduced forms are found in
the active sites of many essential proteins that participate in
key cellular reactions.1–3 However, free Cu ions are potentially
toxic for cells since, due to their redox activity, they may
produce reactive oxygen species.4 Therefore, the intracellular
concentration of Cu is regulated via dedicated proteins that
facilitate uptake, efflux and distribution of Cu (in its reduced
form) to Cu-dependent proteins and enzymes.5–7 In the human
cytoplasm, after the uptake of Cu by Ctr1,8 the Cu chaperone
Atox1 transports the metal to ATP7A and ATP7B (also called
Menke’s and Wilson disease proteins, respectively), two homo-
logous P1B-type ATPases located in the trans-Golgi network.
Once transferred to ATP7A/B, the Cu ion is channeled through
the protein to the lumen of the Golgi where it is loaded onto
specific Cu-dependent proteins and enzymes. Cu distribution
within cells is thought to be driven by gradients of increasing
copper-binding affinity in combination with protein–protein
specific recognition.9
ATP7A/B are multi-domain proteins with several domains
protruding in the cytoplasm as well as membrane-spanning
parts that harbor a channel for Cu. Unique to ATP7/B are six
cytoplasmic metal-binding domains (MBDs; named MBD1 to
MBD6, with MBD1 being the first from the N-terminus and
MBD6 the domain closest to the membrane-spanning part of
ATP7A/B) connected by peptide linkers of various lengths
constituting the N-terminal tail.10 Each MBD in ATP7A/B,
as well as Atox1, has a ferredoxin-like a/b fold and a surface-
exposed invariant CXXC motif (X = any residue) in which a
single Cu can bind to the cysteine sulfurs. In contrast to
the human ATP7A/B, the corresponding bacterial and yeast
P1B-type ATPases have only one or two MBDs. The reason for
the presence of multiple MBDs in ATP7A/B has been proposed
to involve regulation of Cu transfer to the Golgi lumen and
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Cu-mediated protein trafficking between the Golgi and the
plasma membrane.11–14 Since there is no high-resolution struc-
tural information on the arrangement of the six MBDs within full
length ATP7A/B, it is unclear how these domains are arranged
relative to each other at different stages of the catalytic cycle.
Atox1 can deliver Cu to all the MBDs in vitro,15–21 through direct
protein–protein interactions.22,23 It is unclear what MBD(s)
receives Cu from Atox1 in vivo although recent data suggest
MBD2 as the primary target.24 Using Cu transport assays in vitro,
it has been shown that several MBDs can be deleted or mutated
without loss of Cu transport activity, but the presence of at least
one MBD appears to be required.14,25 We have identified various
domain–domain interactions in ATP7B through in vitro and in
silico analyses of multi-MBD constructs26–28 and recent NMR
work beautifully showed that MBD1-3 (in the absence of Cu)
adopted a compact unit that could interact (at least transiently)
with other cytoplasmic ATP7B domains.13,24 Upon Cu delivery by
Atox1 to MBD1-3, the dynamic restrictions on the unit were
released, in accord with a role in Cu-dependent regulation.24,29
Here we used our previously described yeast system25 that
probes Cu transport via Atox1 and ATP7B through growth on
iron-limited media to address the Cu relay path among the
MBDs in ATP7B. In contrast to our previous study, where MBDs
were deleted from the N-terminus one by one, we here intro-
duced Cu site Cys-to-Ser mutations to retain the domains but
only remove the Cu-binding ability. We also tested the ability of
the MBDs, when expressed as individual domains, to replace
Atox1. Our current results, integrated with previous data,24,25
are used to propose a mechanistic model for how Cu is
transported along the MBDs.
Results
The complementation assay builds on the fact that yeast
requires Cu as a cofactor in Fet3p to survive in iron-limited
conditions. Fet3p oxidizes ferrous to ferric iron ions, which are
then taken up by the transmembrane permease Ftr1.14,30,31
Fet3p obtains Cu from the pathway involving the yeast Atox1
homolog, Atx1p, and the yeast ATP7A/B homolog, CCC2p. In
the Dccc2Datx1 double knockout yeast strain (without Atx1p
and CCC2p) there is no functional Cu transport and, therefore,
there is a lack of high-affinity iron uptake and the yeast cells
grow poorly. By supplementing the Dccc2Datx1 strain with the
human homologs of Atx1p and CCC2p on high-copy plasmids,
Cu transport can be restored, which facilitates iron uptake and
improves cell growth.25 Earlier work has demonstrated that
under these conditions, Cu transport limits yeast growth.14,31–33
Here, the Dccc2Datx1 yeast strain supplemented with the human
ATOX1 gene was used as the background in most experiments,
to which high-copy plasmids with mutated ATP7B proteins
were introduced. For all ATP7B variants tested, the yeast growth
rate during the exponential phase was measured (data shown in
Fig. S1, ESI†) and, like previously,25 used as an estimate of the
Cu transport. Although the Cu transport efficiency relates
directly to yeast growth, it is unclear which step(s) within the
processes of Cu transfer from Atox1 to ATP7B, within ATP7B, and
then to Fet3p, is rate limiting under the various conditions.
The single, double, and triple Cu-site mutations introduced
into the six MBDs of ATP7B are listed in Table 1. In all cases
were the two cysteines in the CXXC motif exchanged to serines
in order to block Cu binding. All mutated ATP7B variants were
checked for the protein expression level (examples in Fig. S2, ESI†)
to assure that alterations in yeast growth could be interpreted in
terms of protein function.
Single or triple Cu site mutated ATP7B variants
The data show that if the Cu sites in each domain are mutated
individually, with the presence of the Cu sites in all other
domains, the effect on the overall Cu transport is limited
(Fig. 1A). The largest effects on Cu transport found for individ-
ual domain mutations of Cu sites were found for MBD3 and
MBD6. In contrast, if all three Cu sites in MBD1-3 are mutated,
full Cu transport activity remains, whereas mutation of all three
Cu sites in MBD4-6 results in no Cu transport at all (Fig. 1B and C).
The former results show that MBD1-3 are not needed for full
activity but may instead regulate it (i.e., slow it down). The latter
result shows that one or more of the MBDs closest to the
membrane spanning part (MBD4-6) are essential for Cu transport,
as proposed earlier by yeast complementation experiments.14 To
elucidate further details, we divided the six domains into two
sets, MBD1-3 and MBD4-6, and introduced all combinations of
Table 1 List of constructed ATP7B variants with the Cu sites in the MBDs
changed from CXXC to SXXS (C, Cys; S, Ser; X, any residue; shortened as
CS below and in the text) and indicated in the right MBD with X below. In all
variants, all other domains are present with functional Cu sites. All these
variants were used with Atox1 as the Cu chaperone (Fig. 1)







7 123CS X X X
8 12CS X X
9 13CS X X
10 23CS X X
11 456CS X X X
12 56CS X X
13 46CS X X
14 45CS X X
Table 2 List of constructed ATP7B variants used in combination with
individual MBDs as Cu chaperones replacing Atox1. Here, X means trunca-
tion of the whole domain. Each variant below was tested together with all
six MBDs, one by one, for Cu transport activity (Fig. 2)
No Mutant abbreviation MBD1 MBD2 MBD3 MBD4 MBD5 MBD6
1 ATP7B
2 DEL1-3 X X X
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pairs of Cu site mutated domains within the two sets while
retaining the Cu sites in the other three MBDs (Table 1).
MBD1-3 Cu site mutation combinations
If MBD12 cannot bind Cu, Cu transport is almost as efficient as
with all Cu sites present in MBD1-3. If instead MBD13 or
MBD23 cannot bind Cu, with MBD23 being most dramatic,
the Cu transport is much reduced (Fig. 1B). Thus, when Cu can
bind to MBD3, the Cu sites in MBD12 are not needed for
efficient Cu transport. However, the domains themselves are
needed as truncations of MBD1 or MBD12 resulted in much
slower Cu transport.25 This implies that MBD3 is directly involved
in inhibitory interactions with other ATP7B domains and that
MBD12 must be present to release such interactions upon Cu
loading. This also agrees with the NMR data that directly
showed MBD1-3 to form a cooperative unit that was dissolved
by Cu loading.24
MBD4-6 Cu site mutation combinations
MBD4 alone (like MBD5 or MBD6 alone) can be blocked for Cu
binding without a large reduction of the Cu transport (Fig. 1A).
The decrease in the Cu transport upon mutation of the Cu site
Fig. 1 Growth rates of yeast expressing ATP7B with mutated MBDs (Table 1) as indicated in the Dccc2Datx1 yeast strain complemented with Atox1
plasmid under iron-limited conditions. Error bars are based on standard deviations calculated for quadruplicate experiments in four biological replicas.
(A) ATP7B variants with individual Cu sites mutated. (B) ATP7B variants with two or three Cu sites mutated among MBD1-3. (C) ATP7B variants with two or
three Cu sites mutated among MBD1-3. Controls: S. cerevisiae Cen.pk 113.11C (positive control); Dccc2Datx1, yeast with CCC2 and ATX1 knocked out, no
added plasmids (negative control); ATP7B, Dccc2Datx1 yeast with wild-type, full-length ATP7B and Atox1 plasmids (positive control); Dccc2Datx1 +
ATP7B, Dccc2Datx1 yeast with ATP7B plasmid and without Atox1 plasmid; Dccc2Datx1 + Atox1, Dccc2Datx1 yeast with Atox1 plasmid and without ATP7B
plasmid. The last two conditions also serve as negative controls as both proteins (chaperone and transporter) are needed to facilitate Cu transport.25 The
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in MBD4 may be due to a direct role in the Cu relay from MBD3
to MBD56 or to a structural role (as previously proposed24) that,
via conformational/dynamic changes, facilitates MBD3 to reach
MBD56. In contrast, upon blockage of both the MBD5 and
MBD6 Cu binding sites simultaneously, no Cu transport at all
was detected, although the Cu sites in MBD1-4 are present
(Fig. 1C). Blocking of Cu binding in MBD4 in combination with
in MBD5 or with in MBD6 still results in some Cu transport
activity (Fig. 1C). Thus, the data demonstrate that an intact Cu
site in either MBD5 or MBD6 is absolutely required for Cu
transport. Notably, the presence of a Cu site in MBD6 (without
Cu sites in MBD45) results in higher Cu transport activity than
a Cu site in MBD5 (without Cu sites in MBD46) (Fig. 1C),
implying that the path through MBD6 dominates over the one
through MBD5 for reaching the Cu site in the membrane spanning
part of ATP7B.
MBDs as cytoplasmic Cu chaperones
Both Atox1 and yeast Atx1 can deliver Cu efficiently to ATP7B in
our yeast system.25 To reveal if Atox1 can be replaced with the
individual MBDs in ATP7B, we changed the system and
expressed ATP7B in combination with each MBD as a cytoplas-
mic single-domain protein (expressed on high-copy plasmids)
instead of Atox1 (yeast growth curves shown in Fig. S1, ESI†).
For full-length ATP7B, all MBDs can replace Atox1 and transfer
Cu to ATP7B (Fig. 2A). MBD2, MBD4, MBD5 and MBD6 showed
Fig. 2 Growth rates of yeast expressing individual MBDs instead of Atox1, along with full-length or domain-truncated ATP7B variants (Table 2) as
indicated in the Dccc2Datx1 yeast strain under iron-limited conditions. Error bars are based on standard deviations calculated for quadruplicate
experiments in four biological replicas. (A) Individual MBDs as chaperones and full-length ATP7B. (B) Individual MBDs as chaperones and ATP7B DEL1-3.
(C) Individual MBDs as chaperones and ATP7B DEL1-6. Controls: S. cerevisiae Cen.pk 113.11C (positive control); Dccc2Datx1, yeast with CCC2 and ATX1
knocked out, no added plasmids (negative control); Atox1, Dccc2Datx1 yeast with ATP7B (full length in (A), DEL1-3 in (B), and DEL1-6 in (C)) and Atox1
plasmid. The control of Dccc2Datx1 yeast with only ATP7B plasmid without Atox1 is shown in Fig. 1. Controls with only ATP7B DEL1-3 and ATP7B DEL1-6
plasmids in the absence of Atox1 in Dccc2Datx1 yeast are reported in ref. 25 and match the data for Dccc2Datx1 yeast without any supplemented
plasmids. The Cu transport efficiency for the various combinations (given as % of maximal effect, i.e., the difference between positive and negative
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Atox1-like activity whereas MBD1 and MBD3 as chaperones
resulted in somewhat lower Cu transfer activity. These results
show that all MBDs are well expressed as individual domains and
adopt folded states capable of binding Cu. For ATP7B with
deletion of MBD1-3, i.e., with MBD4-6 remaining, again all MBDs
can replace Atox1 and deliver Cu, although the activity was
somewhat less than with Atox1 as the Cu chaperone (Fig. 2B). If
all six MBDs are deleted in ATP7B, Atox1 cannot deliver Cu to
ATP7B.25 However, with MBD1-6 deleted in ATP7B, we found that
MBD6 as a cytoplasmic domain was able to deliver Cu to ATP7B
whereas all other MBDs failed (Fig. 2C). This result implies that
the MBD6 structural unit makes specific protein–protein interac-
tions near the Cu entry site in the ATP7B membrane part.
Discussion
The yeast S. cerevisiae provides an excellent model to character-
ize Cu transport to the secretory pathway because the proteins
involved in Cu homeostasis are highly conserved from yeast to
humans. Because specific Atox1 interactions appear to be
involved in the Cu transport mechanism among the MBDs in
ATP7B,29 our system, in contrast to previous reports,14,31–33
includes the exchange of the yeast Cu chaperone (Atx1) for the
human one, i.e., Atox1, in addition to exchanging yeast CCC2
for human ATP7B. Although the MBDs have the same fold and
Cu site, there are differences in biophysical properties among
the six domains, such as electrostatic surface potentials, con-
formational dynamics and Cu-dependent structural changes,
and variations in linker lengths between the domains,34–36 that
all may contribute to a preferred Cu transport relay among them.
Our finding that one of the Cu sites in MBD56 is essential for
Cu transport is supported by our25 and others’ earlier work. It
was shown that an intact Cu site in MBD6 was enough to restore
Cu transport when the other MBDs were mutated31 and, in other
studies, it was shown that a mutated Cu site in MBD6 but all
other MBDs being functional,14 as well as with all MBDs present
but only MBD5 with a functional Cu site,31 also promoted Cu
transport. Because of our strategic combination of mutations,
the current results (when merged with earlier findings) make
possible a deepened analysis of how the six MBDs channel Cu in
ATP7B, which is explained below (and illustrated in Fig. 3).
Based on our data, when merged with the truncation data
reported earlier,25 it appears that MBD1-3 forms a regulatory unit
that controls Cu transport. In the absence of MBD1-3 (i.e., ATP7B
with MBD1-3 deleted) there is normal Cu transport;25 in its
presence, full Cu transport is only achieved if MBD3 can bind
Cu. If the Cu site in MBD3 is mutated (Fig. 1B), or if the MBD1 or
MBD12 domains are absent,25 the Cu transport activity becomes
low. We imagine therefore that Cu is delivered to MBD2, as
Fig. 3 Scheme illustrating the major aspects of Cu transport among the MBDs in ATP7B deduced in this study, and taking into account others’ data. Left,
normal scenario. Right, for the case where MBD1-3 have mutated Cu sites. The protein starts in an inhibitory form where MBD1-3 without Cu makes
interactions with other (likely A-, P-, or N-) domains. Cu delivery by Atox1 to one of the MBD1-3 Cu sites, most likely the one in MBD2, results in further
Cu transfer to MBD3. With Cu in MBD3, the domain interactions among MBD1-3 are released due to increased conformational dynamics; this relieves
(inhibitory) interactions with other domains (1). This step can be blocked by mutation of Cu binding residues in MBD3 or by truncation of MBD1 or MBD12
domains. Next, conformational changes, possibly mediated by MBD4 as a spacer, allow MBD3 to deliver Cu to MBD5 or, more likely, MBD6, for Cu
delivery to the membrane-spanning part (2). Mutation of the metal sites in MBD56 abolishes this step, and the MBD6 structural unit is required for correct
docking at the membrane. In our artificial case, where Cu sites in MBD1-3 are mutated, we propose that Atox1 initially delivers Cu to MBD4, and Cu in
MBD4 results in increased structural dynamics providing a pulling force on the MBD34 linker such that the inhibitory interactions between MBD1-3 and
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suggested by earlier data,24,37 and then is channeled to MBD3.
Cu binding to MBD3 releases internal MBD1-3 interactions,
which in turn will release MBD1-3 inhibitory interactions with
other ATP7B cytoplasmic domains. This concept builds on what
was proposed by Dmitriev et al.,24 but specifies that Cu must be
able to reach MBD3 in order to release inhibitory interactions.
Moreover, our earlier findings with truncated ATP7B (MBD1 or
MBD12 absent) do not agree with the N-terminal peptide,
residues 33–66 prior to MBD1,24 being responsible for the
inhibitory interaction. Based on the current results, MBD3 must
make physical interactions with other domains that can only be
released by aid from MBD12. Still, both scenarios may be at play
in vivo in the full length protein.
One puzzling piece of data is the fact that we propose an
inhibitory unit of MBD1-3, but when we mutate all Cu sites in
MBD1-3, we have an ATP7B protein that can transfer Cu rather
well. This implies either that the Cys residues in the empty Cu
sites are important for interactions within the MBD1-3 unit
(e.g., transient disulfide bond formation) or, when no Cu can
enter MBD1-3, instead Cu-Atox1 delivers Cu to MBD4 (which is
the second most favored target after MBD217,38), and Cu placed
in MBD4 also releases the MBD1-3 inhibitory interactions. For a
construct with MBD4-6, it was shown by NMR that Atox1
preferred to deliver Cu to MBD4.38 That Cu-loading of MBD4
releases inhibitory interactions may be mediated by the MBD34
linker, pulling on MBD3 due to altered conformational dynamics
when MBD4 becomes Cu-loaded. Notably, when Atox1 forms a
Cu-dependent complex with MBD4, the entropy of the complex is
increased.22 Also, with Cu in MBD4 in the full length protein as
here, interactions with MBD56 may be favored, which may pull/
strain the MBD34 linker. Since we can make Cys-to-Ser exchanges
in two of the three domains in MBD1-3 (i.e., in MBD13 and
MBD23), and still see inhibition of Cu transport, it does not
appear likely that cysteine disulfides play a role in MBD1-3
internal/external interactions. The most likely scenario is thus
that Atox1-mediated Cu loading of MBD4 can also release MBD1-
3 inhibitory interactions. Notably, this (blockage of MBD1-3 Cu
sites) would not be the normal scenario in vivo as, if possible,
Atox1 would deliver Cu to MBD2 first.24,37 However, it could
relate to regulation: at high Cu levels, i.e., many Cu-loaded Atox1,
MBD4 may also get loaded and that could be a signal to release
inhibition and begin to transfer Cu efficiently.
From MBD3, Cu may be transferred to MBD4 and then to one of
MBD5 or MBD6, or MBD4 simply acts as a linker that allows MBD3
to reach MBD5 or MBD6, so Cu can be moved from one Cu site to
the other via direct protein–protein interactions. It was speculated
that MBD4 is a structural unit merely facilitating Cu transport
between the other domains, as in the mouse and rat ATP7B
homologs, MBD4 has no Cu site.29,39 Still in vitro data showed that
MBD4 can deliver Cu to MBD56, with a preference for MBD6.17 Our
results of somewhat lower Cu transport when the Cu site in MBD4
is mutated may be interpreted within both mechanisms. Impor-
tantly, our data clearly show that none of MBD1-4 can deliver Cu to
the Cu entry site in the membrane-spanning part of ATP7B.
MBD5 or MBD6 may provide parallel routes to the Cu entry
site in the membrane channel, as the Cu site in either of the two
can be deleted without full loss of Cu transport. Nonetheless, for
deletion of either MBD5 or MBD6 Cu sites, Cu transfer is signifi-
cantly reduced, indicating that to obtain maximal Cu transport
both Cu sites (MBD5 and MBD6) are needed. Also the intrinsic
structural unit of MBD6 is essential, independent of the presence
of the Cu site, as only MBD6 as a soluble domain (replacing Atox1)
could deliver Cu to ATP7B when MBD1-6 were deleted (Fig. 2C).
This implies that MBD6 makes compulsory protein–protein inter-
actions with other parts of ATP7B that allow guiding of the Cu ion
to the Cu entry site in the membrane-spanning channel. Based on
an ATP7B structural model, it was proposed that attractive inter-
actions between parts of MBD6 and the P-domain (involving
residues conserved among homologs) may facilitate appropriate
MBD6 positioning near the membrane Cu site.40 Fig. 3 contains a
schematic picture of how Cu transport among the ATP7B MBDs
can be envisioned in the light of the current results.
In Archaeoglobus fulgidus, it was shown that when deleting
the MBDs in the ATPase CopA the soluble Cu chaperone CopZ
could deliver Cu directly to the Cu site in the membrane-
spanning channel.41 This finding is similar to our results here
for ATP7B, but in the human case in this study, the soluble
chaperone (Atox1) and five out of the six MBDs could not do
this job (with truncated ATP7B lacking the six MBDs), only
MBD6. In contrast, none of the MBDs in A. fulgidus CopA, when
expressed as soluble domains, could deliver Cu to CopA, either
with or without MBDs present in CopA. Although here, and in the
A. fulgidus study, the idea of creating soluble MBDs was to assess
reaction mechanisms, it was recently shown that the CopA gene
in E. coli can undergo programmed frameshifting to generate a
soluble truncated protein that includes only the MBD.42 Thus,
both the Cu transporter and the soluble Cu chaperone are made
from the same gene in E coli. Notably, the authors suggested that
similar programmed frameshifting may take place in ATP7B to
generate a shorter version containing only MBD12.42
In conclusion, this study provides further support of MBD1-3
acting as a regulatory unit, in which all three domains cooperate
and, upon Cu loading of MBD3, MBD1-3 interactions with each
other and with other domains are formed, allowing for further Cu
movement along the chain. We also show that a Cu site in either
MBD5 or 6 is sufficient for Cu transport but the MBD6 structural
unit is required to position the MBDs in such a way that allows Cu
to move from MBD5 or MBD6 Cu sites to the metal entry site in the
membrane-spanning part of ATP7B. It would be very interesting to
assess how the here created variants function in ATP7B trafficking,
which may be the major purpose of the MBD1-3 regulatory
interactions. The six MBDs in ATP7B appear to be a system in
which Nature has taken advantage of Cu-dependent variations of
flexibility and conformational dynamics to fine-tune function.
Materials and methods
Yeast strains and plasmid construction
High-stress resistance yeast S. cerevisiae CEN.PK 113-11C (MATa
SUC2 MAL2-8 URA3-52 HIS3-D1; provided by Dr P. Kötter,
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Frankfurt, German) was used as a reference strain. The yeast
strains were cultivated in liquid YEPD/YPD (yeast extract peptone
dextrose media) and grown at 30 1C. The yeast strain bearing
CCC2 and ATX1 deletions was used in this study. For the
expression of ATP7B and ATOX1, plasmids containing human
ATP7B (p426GPD) and ATOX1 (p423GPD) were transformed to
the yeast strain with CCC2 and ATX1 knockout (DCCC2DATX1). The
detailed construction of the yeast strain and plasmids (p426GPD-
ATP7B and p423GPD-ATOX1) was reported previously.25 The
copper binding cysteines (CXXC) in the metal binding domains
of ATP7B were mutated to serines (SXXS). Several combination of
copper site mutations (CS) up to three metal binding domains
were constructed. The mutations were introduced into the full-
length ATP7B by a quick change site-directed mutagenesis kit
using the previously constructed p426GPD-ATP7B plasmid25 as a
template. The constructed ATP7B mutants are listed in Table 1.
The sequences of the six ATP7B MBDs were amplified individu-
ally from the p426GPD-ATP7B plasmid with BamH1 and EcoR1
restriction sites, respectively. Next, the amplified MBD genes
were inserted into the p423GPD vector (ATCC 87355; GDP,
promoter for expression; His3 and ampR, markers). Construc-
tion of ATP7B DEL1-3 (deletion of MBDs 1-3) and DEL-6 (deletion
of all six MBDs) plasmids was previously reported.25 All con-
structed plasmids were verified by sequencing (Eurofins). The
DNA primers used for the plasmid construction are listed in
Table S1 (Cu site mutated ATP7B variants) and Table S2 (indi-
vidual MBDs as chaperones) (ESI†). All plasmids were trans-
formed into yeast cells by the standard lithium acetate method.43
Yeast complementation assay
The copper transport activity of the yeast strains was evaluated
using growth curve analysis in iron limited medium. A single
yeast colony from the plates was inoculated in iron limited
medium (SD medium containing 1.7 g L1 yeast nitrogen base
without Fe and Cu), 50 mM MES buffer pH 6.1, 20 g L1
glucose, 5 g L1 ammonium sulfate, complete supplement
mixture CSM–Ura–His, 1 mM ferrozine (Fe chelator), 1 mM
CuSO4 and 100 mM FeSO4 and incubated overnight at 30 1C
and 200 rpm.30 Yeast cells from this culture were washed with
ice cold deionized water and cultivated in the fresh iron-limited
medium at an initial cell density of OD600 nm = 0.1. The growth
of the cells was monitored using a growth profiler (Enzyscreen
GP960), and growth rates were determined in the exponential
phase. Growth was probed in 96-well plates (250 mL) every
30 min via green (from GP960) absorption, which was con-
verted to OD600 equivalents. All yeast growth experiments were
carried out under identical conditions and in four biological
replicates. Error bars are based on standard deviations calcu-
lated for quadruplicate experiments. Statistical significance
was determined by using two-tailed Student’s t-test.
Protein extraction and Western blot
All yeast strains were grown in iron limited medium for 30 hours
at 30 1C. Cells were spun down by centrifugation at 2000  g at
4 1C for 10 min. Cells pellets were washed twice with ice-cold
water and re-suspended in lysis buffer (50 mM HEPES pH 7.5,
150 mM NaCl, 2.5 mM EDTA, 1% v/v Triton X100 and freshly
added protease inhibitor). After disruption with glass beads,
membranes were collected by centrifugation at 18 000  g (4 1C,
30 min). Samples were re-suspended in SDS loading buffer
(0.5 M Tris–HCl, pH 6.8, 10% SDS, 0.5% (w/v) bromophenol
blue, 87% glycerol, 100 mM DTT) and 50 mg of the membranes
were loaded on a 4–12% Bis–Tris gel (Invitrogen) and blotted
onto PVDF membranes. ATP7B and Atox1 were detected with
monoclonal rabbit ATP7B and Atox1 antibodies, respectively
(Abcam, 1 : 1000 dilution), upon incubation overnight at 4 1C.
Next, blots were incubated with horse radish peroxidase con-
jugated anti-rabbit IgG reagent (Thermo Scientific Pierce) for
15 min, 4 1C. Bands were detected by Piercet fast western blot
kits, SuperSignalt West Femto, rabbit (ThermoScientific Pierce)
and visualized with a BioRad ChemiDoc XRSimage analyzer.
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